Improves the appearance of photoaged skin, including fine lines, density, and firmness, when applied topically.
Why this rating
There is real human evidence here, which puts GHK-Cu ahead of most peptides marketed for skin, and it is weaker than the marketing implies. The most-cited study, a 12-week trial in 71 women, was a 2002 conference presentation rather than a peer-reviewed publication, and much of the supporting literature is written by the peptide's discoverer, who also founded companies selling it. An independent 2025 review concluded that published data on GHK skin permeability and effectiveness remains insufficient. Cosmetic endpoints are also unusually placebo-sensitive, since moisturizing anything for 12 weeks improves how it looks.
GRADE downgrade factors applied
- Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
- Publication bias: Suspicion that negative or null results were not published, inflating apparent effect.
- Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.
Supporting studies
- Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospectiveSystematic ReviewBioImpacts2025
Independent review finding published effectiveness and skin-permeability data insufficient.
- Leyden et al., 12-week facial and eye cream study in 71 women with photoaged skinRandomized Controlled TrialAmerican Academy of Dermatology annual meeting presentation2002n=71
Reported improvements in skin density, thickness, laxity, and fine lines. Conference presentation, not peer-reviewed.